Tag:
Zytiga
Latest Headlines
Latest Headlines
J&J taps top blockbusters in the pipeline, lays out global R&D strategy
Johnson & Johnson built its R&D rep around blockbuster development deals. Now the pharma giant's drug development arm wants the world to know that there's a comprehensive, global pipeline strategy in play that will deliver more than 10 new product applications over the next 4 years. And new drug development efforts in China and Japan are growing to rival the work it does in the U.S. and Europe.
Xs and Zs become popular in drug names
Drug names starting with an X or a Z may be hard to pronounce but that is really the last thing that drugmakers consider when coming up with new names. They want something that is memorable.
Zytiga, Stelara help boost J&J pharma sales
Johnson & Johnson's ($JNJ) earnings surpassed analyst expectations. Its prescription drug sales were up 6.8%, helped by leaps forward in cancer drugs and anti-inflammatories. Its new prostate cancer drug Zytiga fell just a tad short of blockbuster status, and that's without its newly approved label expansion.
J&J's Zytiga gets expanded approval that could double sales
Chalk up an expanded use, and so an expanded market, for Zytiga, Johnson & Johnson's hot but pricey prostate cancer drug.
Zytiga, Xtandi will help pump prostate cancer market to $9.1B
The market for prostate cancer drugs is expected to double by 2021 to $9.1 billion, thanks in part to the debut of new, more expensive drugs. According to Decision Resources, Johnson & Johnson's ($JNJ) Zytiga, along with Medivation ($MDVN) and Astellas Pharma's new Xtandi, will help drive sales growth in 7 major drug markets.
Puma Biotech raises $138M in public offering to advance cancer drug from Pfizer
The company said on Thursday afternoon it sold more than 8.6 million shares for $16 per share, netting $129.1 million and adding to its coffers as the company readies for late-stage development of a potential breast cancer drug in-licensed from the drug giant Pfizer last year.
J&J credits Remicade, Zytiga for 7% hike in Q3 drug sales
Generic competition hit a few of Johnson & Johnson's ($JNJ) big sellers during the third quarter, but other products--including its newest ones--more than filled the breach. The company's pharma division turned in a 7% increase in sales, to $6.4 billion, even after a 4.3 percentage-point currency hit.
No breakup for J&J? Goldman analyst says 'Sell'
Goldman Sachs analyst Jami Rubin can be tough to please. Particularly for companies that aren't jazzed about the idea of splitting themselves into smaller pieces. Hear that, Johnson & Johnson ($JNJ)?
Oxford Bio shares tumble after mid-stage cancer study fizzles out
More than two years ago Oxford BioMedica put out the word that the FDA had cleared a Phase II study for its troubled program for TroVax, an immunotherapy to be tested in 80 patients suffering from hormone resistant prostate cancer. For Oxford, the mid-stage study was a key part of its comeback strategy for TroVax, which had already failed a study for renal cancer in 2008.
Promising prostate cancer data triggers $50M venture haul for Aragon
Just days after reporting positive interim results from a mid-stage study of its closely-watched prostate cancer drug, San Diego-based Aragon Pharmaceuticals has topped up its bank account with a whopping $50 million venture round--bringing its total haul this year alone to $88 million.
